Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

258 Applying Pharmacogenomics in Therapeutics
TABLE 10.5
Gene Polymorphisms and Herb–Drug Interactions
Herbal Medicine Drug Affected Gene Polymorphism Pharmacogenomics in HDIs Effects
Baicalin Rosuvastatin OATP1B1 *1b/*1b; *1b/*15;
*15/*15
Berberine
Evodiamine
Dictamnus
dasycarpus
Pseudoepicoccum
cocos
Rhus verniciflua stokes
Fluoxetine,
sertraline
Digoxin,
daunorubicin
5-HTT S, XS11, XL17,
XL18 alleles and
A>G (rs25531)
MDR1 2677G/T/A
(rs2032582)
After baicalin treatment, the AUC 0–72 and AUC 0–∞ of rosuvastatin were
decreased according to OATP1B1 haplotype *1b/*1b (47.0 ± 11.0%
and 41.9 ± 7.19%), *1b/*15 (21.0 ± 20.6% and 23.9 ± 8.66%), *15/*15
(9.20 ± 11.6% and 1.76 ± 4.89%), respectively.
When tested against the S, XS11, LG, LA, XL17, and XL18 alleles,
100 mm berberine increased 5-HTT promoter activities by 67%,
128.7%, 106.9%, 100.4%, 26.2%, and 82%, respectively, 2 mm
evodiamine increased 5-HTT promoter activities by 216.7%, 81.6%,
305.6%, 181.5%, 175.3%, and 102.2%, respectively.
Digoxin effluxes were significantly decreased in MDR1 gene variants of
2677T/893Ser with the treatment of P. cocos, and of 2677G/893Ala and
2677T/893Ser with the treatment of D. dasycarpus.
Radix Astragali (RA) Fexofenadine ABCB1 C3435T T 1/2 of fexofenadine in ABCB1 3435T mutation allele carriers was longer
compared to ABCB1 3435CC carriers (4.43 ± 1.44 h vs. 2.54 ± 0.21 h),
while RA extract pretreatment lengthened T 1/2 in ABCB1 3435CC
carriers and abolished such genotype-related differences.
GFJ Ebastine MDR1 C3435T The grapefruit juice–induced inhibition of its transport/formation
(mean-fold decrease ± SD: 1.5 ± 0.8, 1.1 ± 0.9, and 0.9 ± 0.4) for CC,
CT, and TT carriers, respectively.
(Continued)